Market Closed - Nyse 04:00:02 2024-06-12 pm EDT 5-day change 1st Jan Change
44.23 USD +0.61% Intraday chart for Qiagen N.V. -0.90% -1.21%
LockThis Alphavalue article, the European leader in independent research, is only available to subscribers .
Alphavalue is exclusively on MarketScreener.
To unlock the article, SUBSCRIBE!
Already a customer? Log In
Qiagen Scraps NeuMoDx 96, 288 Molecular Systems; Raises 2024 Adjusted Earnings Outlook MT
Qiagen to Discontinue NeuMoDx Integrated PCR Testing System CI
Qiagen N.V. Reaffirms Earnings Guidance for the Second Quarter of 2024 CI
Qiagen N.V. Launches Digital PCR Assay Design Tool for QIAcuity, Expands Customization Capabilities of Its Research Platform GeneGlobe CI
Qiagen Expands Qiastat-Dx Syndromic Testing Menu in the U.S. with Launch of Molecular Test to Improve Gastrointestinal Care CI
Qiagen, Myriad Genetics Team Up to Develop Homologous Recombination Deficiency Test MT
Qiagen, Myriad Genetics Partner to Create Easily Distributable Cancer Tumor Test MT
QIAGEN and Myriad Genetics Develop Distributable Homologous Recombination Deficiency Test for Global Research and Companion Diagnostics Applications CI
Qiagen N.V. Launches New Library Preparation Kit, Facilitating Multiomic Studies and Advancing Precision Medicine CI
QIAGEN NV : Berenberg maintains a Buy rating ZD
Qiagen's Updated Clinical Decision Support Platform Secures EU Certification MT
QIAGEN Receives European IVDR Certification for QIAGEN Clinical Insight Interpret CI
Qiagen Receives FDA Clearance for Clinical Use of Respiratory Infection Test MT
Qiagen Obtains US FDA Clearance for Respiratory Syndromic Testing Panel MT
Qiagen Receives FDA Clearance for Qiastat-Dx Respiratory Syndromic Testing Panel for Fast and Accurate Results CI
Qiagen, US FBI to Jointly Develop Digital PCR Assay for Forensics MT
QIAGEN Partners with FBI to Develop Digital PCR Assay for QIAcuity for Use in Forensics CI
QIAGEN  Announces the Availability of QCI Secondary Analysis CI
QIAGEN NV : Berenberg reaffirms its Buy rating ZD
QIAGEN : A decent start to 2024; guidance unchanged Alphavalue
QIAGEN NV : Deutsche Bank reiterates its Buy rating ZD
Qiagen Seeks Acquisitions CI
Transcript : Qiagen N.V., Q1 2024 Earnings Call, Apr 30, 2024
QIAGEN NV : Jefferies remains Neutral ZD
QIAGEN NV : UBS remains Neutral ZD
Chart Qiagen N.V.
More charts
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
44.23 USD
Average target price
50.14 USD
Spread / Average Target
  1. Stock Market
  2. Equities
  3. QGEN Stock
  4. News Qiagen N.V.
  5. Qiagen: A decent start to 2024; guidance unchanged